1. Introduction
===============

Peripheral nerve disorders are frequent complications of HIV disease. Distal symmetrical polyneuropathy (DSP) is the most common peripheral nerve disorder associated with HIV ([@bib83]). About 40% of ambulatory HIV patients in the developed world population have peripheral neuropathy, a prevalence which has not altered with the advent of antiretroviral therapy ([@bib77]). Of these 74--93% have pain, which is severe in 37--43% of patients. In addition, 52% of people living with advanced HIV have peripheral neuropathy associated with symptoms such as pain ([@bib74]). The most common clinical features of DSP are measurable sensory abnormalities, most noticeably loss of sensitivity to thermal stimuli ([@bib57]) and on-going, paroxysmal or stimulus evoked pain ([@bib19; @bib56]). There are two predominant (and clinically similar) settings in which painful DSP may occur in HIV disease. First, a disease-related DSP associated with HIV disease, likely involving virally mediated mechanisms such as the interaction of the coat protein, gp120, with sensory neurones precipitating chemokine mediated neuronal damage ([@bib63; @bib47; @bib58; @bib84]) and; second a drug-induced DSP, particularly associated with the use of nucleoside reverse transcriptase inhibitors as part of an anti-retroviral therapy ([@bib13; @bib14; @bib85]).

We have characterized a model of HIV-related neuropathy, termed gp120 + ddC ([@bib85]), which combines perineural administration of the HIV-1 coat protein, glycoprotein 120 (gp120), with systemic treatment with the nucleoside reverse transcriptase inhibitor, 2′, 3′-dideoxycytidine (ddC/Zalcitabine). Gp120 + ddC treatment is associated with development of hypersensitivity to static punctate mechanical stimuli, without hypersensitivity to heat or cold, and thigmotaxis (anxiety-like behaviour) ([@bib85]). This model represents one clinical scenario of DSP in the HIV patient treated with nucleoside reverse transcriptase inhibitors, whereby the sensory neurones are damaged by a combination of gp120 and ddC effects ([@bib13]). In this study, the gp120 + ddC model is used to elucidate the pathophysiology of DSP using gene microarrays of dorsal root ganglions.

To distinguish between genes that are directly related to the sensory dysfunction observed in the gp120 + ddC model and those that are related to other aspects of the pathophysiological response to a nerve lesion, we compared the gp120 + ddC-evoked gene expression with that measured in a model of traumatic neuropathic pain, the L5 spinal nerve transection model (L5 SNT), where hypersensitivity to a static mechanical stimulus is also observed. This is a well established and commonly employed model of peripheral nerve lesion in rats and results in hypersensitivity to mechanical, cold and heat stimuli. ([@bib49; @bib16; @bib70; @bib11]). Variants on this model have been utilized in previous microarray investigations ([@bib86; @bib81; @bib51; @bib53]) making this an appropriate comparator model for this study. By comparing gene expression profiles in these two distinct models, we aim to highlight genes associated with HIV-related neuropathy as well as mechanical hypersensitivity in neuropathic pain conditions in general.

2. Methods {#sec1}
==========

2.1. Animals
------------

All experiments conformed to the British Home Office Regulations and IASP guidelines ([@bib92]). Male Wistar rats weighing 200-250 g at baseline were used for all experiments (B&K, Hull, UK) and were housed in a temperature-controlled environment, maintained on a 14:10 h light--dark cycle (experiments were performed during the light phase) and provided with feed and water *ad libitum*.

2.2. Experimental animals
-------------------------

### 2.2.1. Spinal nerve transection model (SNT)

Surgery was performed under general anaesthesia (1--2% isoflurane in 1% O~2~ and 1% N~2~0), using standard aseptic techniques. SNT (*n* = 12) surgery was performed as previously described ([@bib11]). Using the transverse processes of L6 as a guide, the left paraspinal muscles were exposed and separated from the spinous processes. The L6 transverse process was then removed by hemi-laminectomy and the L5 spinal nerve exposed, ligated tightly with a 3--0 silk suture, and cut 1 ± 2 mm distal to the suture. Sham surgery (*n* = 12) was performed by exposing the L5 spinal nerve as described above, but not damaging it.

### 2.2.2. Gp120 + ddC model

Rats in this model were treated as described by [@bib85]. In eight anaesthetized (1--2% isoflurane in 1% O~2~ and 1% N~2~0) rats the left sciatic nerve was exposed to gp120 by placing a 5 mm × 2 mm piece of gel foam soaked in saline containing 200 ng HIV-1 gp120-MN (\>95% pure; Immunodiagnostics, Bedford, MA, USA) in direct contact with the nerve, to form a pool of protein solution around the nerve that is left in place for 30 min. Following this, oxidized regenerated cellulose (Surgicell, Ethicon); previously soaked until saturation in the same saline-gp120 solution, was wrapped loosely around the sciatic nerve 2-3 mm proximal to the trifurcation so as not to cause any nerve constriction and left *in situ*. The nerve was gently manipulated back into place and the muscle and skin incisions closed with 4/0 silk sutures. Animals were injected on the day of surgery with ddC (Roche, Basel, Switzerland; 50 mg/kg in saline, i.p.) and injected thereafter three times per week. Fourteen days after the day of surgery animals were sacrificed and DRG tissue was collected. Sham surgery (*n* = 8) was performed by exposing the left sciatic nerve as described above, but exposing it to 0.1% rat serum albumin. The sham group also received saline as a control for ddC.

### 2.2.3. Varicella Zoster Virus (VZV) infection model

We used an additional model of neuropathic pain, the VZV infection model, for validation of the differential expression of three of our candidate genes by RT-PCR and immunoblot analysis. Rats in this model were treated as previously described by [@bib40]. In brief, VZV (strain Dumas) was propagated on fibroblast (primary human embryonic lung) cells and harvested when cells exhibited 80% cytopathic effect (cpe) (equivalent to 10^4^--10^5^ plaque forming units). Animals (*n* = 16) were subcutaneously injected with 50 μl viral inoculum into the mid-plantar glabrous footpad of the left hind limb. Control animals (*n* = 16) received similar injection of uninfected fibroblast cells. Fourteen days after the injection, animals were sacrificed and L4 and L5 DRG tissue was harvested.

2.3. Behavioural reflex testing
-------------------------------

Punctate mechanical hypersensitivity was assessed using graded "von Frey" nylon filaments (Alan Ainsworth, UCL, London), which were used to deliver a calibrated indentation pressure against the hairless skin of the hind paws. The withdrawal threshold was determined by sequentially increasing and decreasing the stimulus strength and threshold response was defined by the nominal bending force of the filament that evoked foot withdrawal at least three times in every five applications when delivered at a rate of 1 Hz ([@bib12]). Baseline measurements were obtained for all animals on two separate occasions within the week prior to surgery. Following surgery, behavioural reflex tests were carried out in a blinded manner. Animals were re-tested on day 14 post-surgery/infection and only animals demonstrating a significant (paired *t*-test, *p* \< 0.05) reduction in ipsilateral PWT compared to baseline values were retained for microarray analysis.

2.4. Tissue collection and microarray
-------------------------------------

Animals were sacrificed by administration of an overdose of pentobarbitone (100 mg/kg Animalcare Ltd., York, UK). Ipsilateral DRG from lumbar segments L4 and L5 were dissected on ice, and snap frozen in liquid nitrogen. Transection of the L5 spinal nerve in the SNT model was confirmed on post-mortem and only these animals were included in the microarray analysis. Prior to RNA preparation, for the gp120 + ddC model, ipsilateral L4 and L5 DRGs from two animals were pooled, to provide enough tissue for RNA preparation. For the SNT model, only ipsilateral L5 DRGs from three animals were collected and pooled. Four replicates per condition were prepared. Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsband, CA, USA), and further purified using an RNeasy Mini kit (Qiagen, Crawley, UK), according to the manufacturer protocols. Affymetrix GeneChip® Rat Genome 230 2.0 arrays (Santa Clara, CA, USA) that study over 30,000 transcripts and variants from over 28,000 well-substantiated rat genes, were used for these experiments. Biotin labeled cRNA was generated using the Affymetrix Small Sample Labeling Protocol vII (<http://www.affymetrix.com>). Approximately 200 ng total starting RNA was used for each sample. Labeled cRNA fragmentation, as well as array hybridization, washing, and staining were performed as described in the Affymetrix GeneChip® Expression Analysis Technical Manual (<http://www.affymetrix.com>).

2.5. Data analyses
------------------

CEL files were obtained with Affymetrix Microarray Suite software. Data was analysed using R v2.3.1 and Bioconductor v1.8 packages ([@bib35]) as follows: Quality control tests and RMA data normalization were performed using Simpleaffy ([@bib90]) and Affy ([@bib33]). The normalized data was filtered, using Genefilter (<http://www.bioconductor.org/packages/1.8/bioc/html/genefilter.html>), to remove probe sets with minimal expression levels (i.e., probe sets failing to have a signal higher than log~2~(100) in three or more arrays). Statistical analysis was performed using linear models and empirical Bayes methods implemented in the Limma package ([@bib75; @bib76]). Benjamini and Hochberg's step-up method ([@bib69]) with false discovery rate (FDR) less than 0.1 was used to control for multiple testing. The threshold *p* value consistent with an FDR near 10% was identified as 0.03 for the SNT model (10.4% FDR) and 0.004 for the gp120 + ddC model (9.6% FDR). The lists of statistically significant genes were loaded into GeneSpring GX (v7.3.1) software (Agilent Technologies, Cheshire, UK), where a second filter (fold difference less than 1.2-fold) was applied to further reduce false positive results ([@bib6]). We chose 1.2-fold change, which is a moderate cut-off, to signify differential expression, because the two cycle amplification protocol used in this study is thought to suppress fold differences (see discussion). Finally, Venn diagrams were used to cross-compare data between models. The microarray data is available in MIAME-compliant (minimum information about a microarray experiment) format at the ArrayExpress database (<http://www.ebi.ac.uk/arrayexpress>) ([@bib67]) under accession codes E-MEXP-974, E-MEXP-976.

### 2.5.1. Functional association analysis

Associations with the annotations of the Gene Ontology (GO) Consortium ([@bib4]) were obtained, for the lists of significant probe sets (10% FDR and over 1.2-fold difference) that correspond to each model, using MAPPFinder 2.0, a part of the GenMAPP 2.1 application package ([@bib18; @bib27]). To ease the interpretation of results, output data were manually filtered, using criteria used by [@bib27], to remove terms that represented the same genes (typically parent--child processes). For a process to be included in the results, it was required that the *z* score from the MAPPFinder statistics was higher than 2, with a permute *p* value less than 0.01, and that at least one gene changed significantly for this node (local results). Also, terms that (a) comprised of 5 or less genes; or (b) had more than 200 genes changed (nested results) were removed, because they were either too specific or too general for the data interpretation.

Pathway analysis was also performed using Gene Set Enrichment Analysis (GSEA) version 2.0 ([@bib79; @bib78]). A total of 253 gene sets were applied. These were obtained from the C2/Canonical Pathways collection of MSigDB version 2.1 ([@bib79]), which contains gene sets collected from various sources such as online pathway databases, publications in PubMed, and knowledge of domain experts. Fourteen additional gene sets were generated by querying the Affymetrix NetAffx tool ([https://www.affymetrix.com/analysis/netaffx/index.affx](http://www.affymetrix.com/analysis/netaffx/index.affx)) with pain related key words. GSEA was run with default settings by using the gene_set permutation option and performing 1000 gene permutations for the determination of statistical significance. Significant FDR and *p* values were less than 25% and 0.01, respectively, in accordance with GSEA recommendations.

2.6. RT PCR
-----------

RT-PCR was performed as previously described ([@bib10]). The sequence of primers used is listed in [Table 1](#tbl1){ref-type="table"}. New pools of DRG RNA from SNT-, gp120 + ddC- and VZV-treated animals were used for these experiments. DRG RNA was extracted by using guanidine isothiocyanate. Total RNA (2 μg) from L4 and/or L5 DRGs of sham or treated animals (*n* = 3 per group) was treated with DNase I, and cDNA was synthesized with Superscript reverse transcriptase (Invitrogen, Paisley, UK) using random hexamers in a total volume of 20 μl. In order to identify the optimal conditions for a linear range of amplification in the quantitative RT-PCR analysis, the amount of each amplified product was first checked at 24, 27, 30, 33, 36, and 39 cycles. Portions of the reverse-transcribed solution (0.5 μl) of total RNA from treated or sham ganglia were used for PCR. Each PCR (94 °C, 30 s; 58 °C, 30 s; 72 °C, 1 min; 33 cycles, 30 μl) was started with the primer pair specific for genes of interest (see [Table 1](#tbl1){ref-type="table"}). The primer pairs for cyclophilin A (PpiA) were added to the PCR reaction 5 cycles after the start. PCR products (10 μl) were visualized on 1.5% agarose gels, using ethidium bromide. The intensity of each band was analysed using Image J software (<http://rsb.info.nih.gov/ij/>) and normalized to cyclophilin A. To test for differential expression, a Student's *t* test with a significance level of *p* \< 0.05 was used.

2.7. Western Blots
------------------

Protein extraction, SDS--PAGE, and Western blotting were performed as previously described ([@bib64]). DRG were isolated and snap frozen, and protein was extracted by homogenization in RIPA buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 1 μg/ml each aprotinin, leupeptin, pepstatin) followed by centrifugation at 10,000 g for 10 min. The protein concentration of the supernatant was determined by Bradford assay, and 50 μg protein was applied to each lane of 12% SDS--PAGE. Wet transfer was performed using Hybond ECL (Amersham), and the membrane was blocked for 60 min in 5% non-fat dried milk in TBS-T (50 mM Tris-HCl, pH 7.6, 140 mM NaCl, 0.1% Tween 20). The blot was probed with goat anti-Reg2/Pap (1:1000 dilution, R&D systems), rabbit anti-Atf3 (1:500 dilution, Santa Cruz Biotechnology) and anti-Actin (1:5000, Sigma) antibodies. Results were visualized with horseradish peroxidase-coupled anti-goat or anti-rabbit immunoglobulins (Dako) using ECL Western blotting detection system (Amersham).

3. Results
==========

3.1. Mechanical hypersensitivity data
-------------------------------------

At day 14 post-intervention, all animals displayed hypersensitivity to a punctate mechanical stimulus, in the limb ipsilateral to treatment ([Fig. 1](#fig1){ref-type="fig"}). This has been previously established to be the time of maximal mechanical hypersensitivity in both models ([@bib28; @bib85]). On average there was an 80% reduction from baseline in gp120 + ddC-treated animals and a 75% reduction in SNT-treatment. Mechanical hypersensitivity was not observed in the contralateral paws of the treated animals (data not shown), nor in the ipsilateral paws of sham animals.

3.2. Model-specific differential expression of genes
----------------------------------------------------

The microarray experiment was conducted at one time point post-injury (day 14) and consisted of two conditions per model (treated animal versus sham) with four replicates per condition. To test for outlying chips, a number of quality control tests were carried out on the raw and RMA normalized data files (data not shown), which resulted in the exclusion of one of the replicates for the treated SNT animals.

We defined differentially expressed genes using criteria of 10% FDR and overall fold difference from sham \>1.2 (see Section [2](#sec1){ref-type="sec"}). Of the approximately, 30,000 transcripts queried on the Affymetrix GeneChip® Rat Genome 230 2.0 array, 656 probe sets were significantly disregulated in the gp120 + ddC DRGs. Of those, 243 were upregulated versus sham, whereas 413 were downregulated ([supplementary tables 1 and 2](#app1){ref-type="sec"}). In SNT DRG, 2696 probe sets were upregulated versus sham and 2444 downregulated ([supplementary tables 3 and 4](#app1){ref-type="sec"}). Moreover, considering fold changes alone, while only 40 probe sets showed over 2-fold expression differences between sham and treated animals in the gp120 + ddC model, 1593 probe sets showed over 2-fold difference in the SNT model. We interpret this as a reflection of the moderate amount of nerve damage induced in the sciatic nerve in the gp120 + ddC models, which is in contrast to the extensive trauma inflicted in the SNT model.

3.3. Comparison of SNT data with the literature
-----------------------------------------------

To verify the accuracy of the microarray results, we compared our SNT model results with two published microarray datasets describing differential gene expression (13 or 14 days after injury) in the DRG of rats subjected to spinal nerve ligation (SNL) ([@bib86; @bib81]). Our SNT model is a variation of the SNL model and thus our data are comparable to the SNL datasets. Both previous studies used rat RG-U34A arrays that contain 8799 probe sets and published lists of differentially expressed genes that show greater than 2-fold difference with *p* \< 0.05. They compared ipsilateral to contralateral pools of L4, L5, and L6 DRG. Despite these analytical and methodological differences to our study, the data are expected to show strong similarities. [@bib86] identified 102 upregulated and 46 downregulated genes, while [@bib81] identified 98 upregulated and 113 downregulated genes. We merged these lists and identified probe sets for a total of 195 genes in the Rat Genome 230 2.0 array that we employed in this study. Hundred and fifty-nine of these probe sets (81.5%) are significant in our SNT dataset, with *p* \< 0.04 (FDR \< 0.1) and over 1.2-fold difference in the same direction as the previously reported studies. For a more detailed breakdown of these results, see [supplementary Table 5](#app1){ref-type="sec"}. The correlation between the SNT results and published observations substantiates the accuracy of our data.

3.4. Gene Ontology results
--------------------------

We used MAPPFinder/GenMAPP and GSEA to perform a general search for pathways associated with gp120 + ddC treatment. With MAPPFinder/GenMAPP we found that 50% of the 243 significantly upregulated and 48% of the 413 downregulated genes in this model are linked to a GO term. Eleven GO functional annotation terms are over-represented in the upregulated gene list, neuropeptide signalling being the most significant ([Table 2](#tbl2){ref-type="table"}). Several other terms are related to organ development (e.g., tube morphogenesis, axonogenesis). Three GO terms are over-represented in the downregulated gene list ([Table 2](#tbl2){ref-type="table"}). They are all related to chloride channel activity (GABA-A receptor activity, chloride ion binding, chloride channel activity).

The GSEA software was used to obtain a more detailed classification of the data into various affected pathways. GSEA considers all of the genes in an experiment, not only those above an arbitrary cut-off in terms of fold-change or significance. When GSEA was applied to the gp120 + ddC dataset, 20 gene sets were found to be up-regulated (FDR \< 2.5 and *p* \< 0.01) ([Table 3](#tbl3){ref-type="table"}). These include five gene sets that involve calcium dependent signalling (G alpha q pathway, Wnt/Ca2+/cyclic GMP pathway, calcium regulation in cardiac cells pathway, Pyk2 pathway and calcium homeostasis) and three cell adhesion gene sets (cell adhesion molecule activity, Brentani cell adhesion and GO cell adhesion). This is in agreement with the MAPPFinder results. The upregulation enriched gene sets also include a list of pain related genes. The genes that contribute to the high enrichment score for this gene set are illustrated in [Fig. 2](#fig2){ref-type="fig"}. Twelve gene sets are downregulated in the gp120 + ddC model ([Table 4](#tbl4){ref-type="table"}). They include a gene set of ribosomal proteins, three gene sets related to proteasomes and two for RNA/DNA transcriptome reactome genes.

In the SNT model data, 44% of the significantly upregulated and 43% of the downregulated genes are linked to a GO term. As shown in [supplementary Table 6](#app1){ref-type="sec"}, the majority of biological process GO terms identified as significant in the list of upregulated genes are linked to neuroinflammation and immune system activation, highlighting the presence of dramatic neuroinflammation in SNT DRG. In contrast, multiple GO terms linked with ion transport (especially potassium ion transport), cell--cell signalling and cell communication are identified as significant in the list of downregulated genes. The obtained results agree with [@bib86; @bib81] and provide another level of validation of our experimental results. The same pathways were also identified using GSEA analysis ([supplementary tables 7 and 8](#app1){ref-type="sec"}). Interestingly, the gene set containing pain related genes is amongst those linked with down regulation in the SNT model. A detailed breakdown of the genes that contribute to the high enrichment score for this gene set are illustrated in [Fig. 2](#fig2){ref-type="fig"}.

3.5. Model cross comparisons
----------------------------

To identify genes that are relevant to mechanical hypersensitivity, we compared the lists of differentially expressed genes in both models, created using criteria of 10% FDR and overall \>1.2-fold difference from sham, with Venn diagrams (see [Fig. 3](#fig3){ref-type="fig"}). We found 14 probe sets that are commonly upregulated in the DRGs of SNT and gp120 + ddC treated animals ([Table 5](#tbl5){ref-type="table"}). Only one of these is an EST of unknown function. The remaining probe sets correspond to annotated genes which can be subdivided into four groups on the basis of their function: signal peptides (Pap/Reg2, NpY, Scube1, Vgf), ion/protein transporters (Atp2B4, Dlg5, Slc4a8), transcription factors (Arnt2, Bptf, Irf7, Midn, Per2) and a cell differentiation molecule (Lama5) ([Table 5](#tbl5){ref-type="table"}).

Twenty-five probe sets corresponding to 24 genes or ESTs were downregulated in the DRGs of SNT and gp120 + ddC treated animals ([Table 6](#tbl6){ref-type="table"}). Thirteen of these have unknown function while the remaining eleven are implicated in a variety of processes varying from metabolism (Gla, Fpgt, St8sia3), to ion/protein transport (Efcbp1, Kif5a, Rab27b, Sv2b), transcriptional activation (Esrrg), mitochondrial function (Senp5) axon guidance (Robo2) and signal transduction (Nkiras1).

3.6. RT-PCR and immunoblotting results
--------------------------------------

We sought to confirm the gene expression changes of a selected subset of genes using semi-quantitative RT-PCR analysis. Cyclophilin A was used as internal control.

First, we measured the truncated isoform of TrkB (TrkB.T1), a receptor for BDNF ([@bib41]) as this was the most upregulated gene in the gp120 + ddC DRG ([supplementary information table 3](#app1){ref-type="sec"}). The Affymetrix GeneChip® Rat Genome 230 2.0 array also contains a probe set (1368972_at) that corresponds to the full length isoform of this gene (TrkB.FL). It showed no significant change in expression between treated and sham animals. We designed primers specific for TrkB.FL, for TrkB.T1 as well as for a second truncated isoform of TrkB (TrkB.T2) which is absent from the microarray. Only TrkB.T1 was found to be up-regulated in gp120 + ddC treated animals supporting the microarray findings ([Fig. 4](#fig4){ref-type="fig"}).

We also measured levels of NpY, Pap/Reg2 and Vgf, the three neuropeptides that are commonly upregulated in SNT and gp120 + ddC models, by RT-PCR. All three genes were found to be markedly upregulated in agreement with the microarray results ([Fig. 5](#fig5){ref-type="fig"}). As a further test for the link between these genes and mechanical hypersensitivity, we also measured the differential expression of these three genes in L4 and L5 DRG of rats infected with Varicella Zoster virus. This is a disparate animal model of neuropathic pain, used to model the mechanisms underlying post-herpetic neuralgia ([@bib71; @bib31; @bib21; @bib32]), which is also associated with similar mechanical hypersensitivity and thigmotaxis behaviour as is observed in SNT and GP120 + ddC ([@bib40; @bib85]). All three genes were also upregulated in the VZV treated animals ([Fig. 5](#fig5){ref-type="fig"}).

We further confirmed the upregulation of PAP/Reg2 using immunoblot analysis to test if the observed mRNA level changes are maintained at the protein level. Pap/Reg2 was found to be upregulated by 1.4-fold for gp120 + ddC, 1.4-fold for SNT and by 1.1-fold for VZV ([Fig. 6](#fig6){ref-type="fig"}) further validating our microarray results.

4. Discussion
=============

To elucidate the mechanisms underlying HIV DSP pain, we performed gene expression profiling in the L4 and L5 DRG of a recently developed rat model (gp120 + ddC) ([@bib85]). We then focused our analysis towards the identification of genes that are directly relevant to presentation of mechanical hypersensitivity. To do so, we compared the gene profile of the gp120 + ddC model, with that of a model of direct sciatic nerve trauma (SNT) that although based on a distinct aetiology, shares the common outcome of mechanical hypersensitivity. As predicted, the models are associated with distinct sets of gene expression changes. However, we identified 39 genes/ESTs that are differentially regulated in the same direction in both models which may therefore underlie the common link of mechanical hypersensitivity.

Gp120 and nucleoside analogues are thought to affect cells by a variety of mechanisms including via cytokine and chemokine signalling pathways ([@bib63; @bib8]). Accordingly, many biological process pathways overrepresented in the gp120 + ddC upregulated gene list involve signal transduction, such as neuropeptide signalling and the G alpha q pathway. Upregulated genes associated with these terms include TrkB.T1, Penk1, Celsr3, Nfkb2 and Itpr3. Interestingly, of these genes, the truncated isoform of TrkB (TrkB.T1), a receptor for BDNF ([@bib41]), is the most upregulated gene in the gp120 + ddC model, which was further validated with RT-PCR. TrkB full length isoform (TrkB.FL)-BDNF signalling has been shown to protect neurons from gp120 induced cell death ([@bib59]), but also thought to contribute to pain facilitation ([@bib36]). TrkB.T1 is thought to modify the action of full length TrkB (TrkB.FL) signalling ([@bib9; @bib29; @bib37]) and thus it is an interesting candidate for the development of hypersensitivity in the gp120 + ddC model.

DdC is associated with mitochondrial toxicity ([@bib20; @bib46]), while gp120 may cause axonal degeneration directly through activation of a mitochondrial caspase pathway and indirectly through neuronal apoptosis mediated by the activation of Schwann cells ([@bib58]). GSEA analysis identified a gene set of ribosomal proteins as significantly associated with downregulation in the gp120 + ddC model. This set contains genes like Rps24, Rps27a, Rps25, and Rpl7.

The mitochondrial dysfunction induced by ddC alters calcium homeostasis in cultured DRG neurons ([@bib88]) and in a model of ddC-associated painful peripheral neuropathy ([@bib45]). Gp120 is also associated with an increase in \[Ca^2+^\]~*i*~ in subsets of cultured DRG cells through the activation of chemokines ([@bib63]). Therefore, alterations in calcium activity could underlie a synergistic effect of a combination of gp120 and ddC exposure. Such synergism of the treatments is suggested by the fact that behavioural indices of pain are enhanced in the gp120 + ddC model as compared to either treatment alone ([@bib85]). We find that several genes involved in calcium ion transport (Casr, Plcg1 and Atp2a2) and calcium binding (e.g., Bcan, Egfl4, Dag1, Stat3, Capn1) are upregulated in the gp120 + ddC model suggesting that changes in calcium regulation may contribute to the development of neuropathy and merit further investigation.

Comparison of the gp120 + ddC and SNT model DRG gene expression profiles indicates that the pathological processes inherent to each model influence multiple gene expression pathways. For example, pathways involved in signalling or cell--cell adhesion are mainly downregulated in the SNT model and upregulated in the gp120 + ddC model. Interestingly, certain genes implicated in neuropathy formation and/or maintenance showed opposing patterns of differential expression between models. For example; protein kinase C, epsilon (PKCε) and its signalling pathways have been implicated in primary afferent nociceptor sensitization ([@bib48]) and it is considered an important contributor to the development of painful diabetic neuropathy ([@bib1]), taxol-induced painful peripheral neuropathy ([@bib24]), painful alcoholic neuropathy ([@bib25; @bib26]), and inflammatory hyperalgesia ([@bib48; @bib3; @bib23; @bib66]). PKCε was down regulated in SNT DRG and up-regulated in gp120 + ddC DRG. The calcitonin-related polypeptide alpha (Calca) gene, that codes for CGRP, which has been implicated in the development of thermal hypersensitivity in mice ([@bib60]) and mechanical hypersensitivity in a traumatic model of rat ([@bib44]). Calca was found to be downregulated in the SNT model, but showed no significant changes in expression for the gp120 + ddC model, which is in line with previous investigations ([@bib85]). This suggests that although these genes have been deemed important in traumatic neuropathy, they may not be associated with neuropathic pain of multiple pathophysiological origins or the manifestation of mechanical hypersensitivity.

There are some limitations of our experimental approach which require discussion. First, this study focuses on a single time point, when mechanical hypersensitivity is well established. Thus the genes identified are potentially important for this phase of mechanical hypersensitivity. To fully identify candidate genes for hypersensitivity generation and maintenance, this study would have to be repeated at a number of time points, which is prohibitively expensive given the current cost of this technology. Secondly, these microarray data reflects changes in gene expression in the entire DRG, which is a heterogenous tissue, composed of many cell types. Thus, this study cannot link changes to specific cell types in the DRG. *In situ* hybridization and/or immunohistochemical experiments are required to further clarify this point. Thirdly, in an effort to minimize animal usage and reduce biological variability, we employed a 2 cycle amplification protocol to generate the microarray targets. The 2 cycle amplification protocol produces reproducible results with high correlation between amplified and non-amplified RNAs ([@bib72; @bib50; @bib54]). However, RNA amplification may cause slight distortion (mainly decrease) of the expression ratios ([@bib22]) and failure to detect transcripts from the low intensity range ([@bib82]). Therefore, our data might suffer from a slight increase in false negative results. This offers an explanation as to why differential expression for ATF3, Galanin, CCL2 and GFAP were detected by immunohistochemistry ([@bib85]) but not by microarrays for the gp120 + ddC model (which exhibits subtle gene changes). Finally, we used a model of HIV-related neuropathy that includes two insults to the nervous system, gp120 and ddC, instead of the insults been applied individually. This model is clinically relevant since the decision to commence antiretroviral therapy is taken at a time when there is a high viral load and therefore circulating gp120 levels are high, with patients being simultaneously exposed to the double neurotoxic insults of gp120 and antiretroviral drugs ([@bib34; @bib85]). However, whereas our model reflects the clinical situation, we cannot be certain whether it is gp120, ddC or the combination which drives the gene changes seen.

Despite the potential limitations of this microarray study, we identified several potential targets for mechanical hypersensitivity maintenance. Thirty-nine genes/ESTs are differentially regulated in the same direction in both of our models. Of these genes, NPY has previously been suggested to contribute to nerve injury-induced mechanical hyperalgesia ([@bib89; @bib65; @bib43]). However, the majority of genes highlighted by our experiment represent potential novel targets in pain processing, two of which are discussed in more detail below.

Vgf is upregulated in the DRG of both gp120 + ddC and SNT models. VGF expression is induced by neurotrophins such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) which are themselves important in the development, maintenance and normal functioning of neurons in the nervous system ([@bib52; @bib15; @bib73; @bib2]). The majority of experimental work on VGF peptide has focused upon its role as an energy homeostasis regulator ([@bib39; @bib38; @bib87; @bib7]) whilst the precise mechanism of VGF action and its role in pain requires further study. However, it is known that in the PNS, VGF is expressed mainly in small to medium diameter sensory neurons that project to the superficial laminae of the spinal cord ([@bib30]). VGF is a secreted polypeptide ([@bib68]), and thus may potentially mediate neuronal communication. Furthermore, another function of VGF is synaptic strengthening associated with learning ,memory and anti-depressant like behavioural effects ([@bib2; @bib80; @bib42]). VGF has also been shown to be up-regulated in rat DRG at 2--28 days following axotomy ([@bib91; @bib17]). Although, axotomized rats do not develop mechanical hypersensitivity of the hind-paw due to deafferentation, VGF is also implicated as an important target in this model and clearly merits further investigation with regard to its role in pain.

Pap/Reg2 was also significantly up-regulated in both models. Reg-2 is a macrophage chemoattractant that is dynamically expressed in rat sensory neurons after peripheral nerve injury ([@bib5; @bib61; @bib62]) and has been implicated in regeneration of motor and sensory neurons ([@bib55; @bib62]). This regenerative role may account for the increase in SNT DRG as compared to the gp120 + ddC model. However, although largely expressed by injured neurons, Reg-2 has also been shown to be upregulated in uninjured axons also ([@bib5]), which may implicate a non-regeneration associated role that may relate to mechanisms of hypersensitivity. The role of Reg-2 in pain is yet to be determined and our results suggest that this may be a good candidate to investigate for such properties.

This study has identified 39 potential mechanical hypersensitivity related genes/ESTs associated with the development of mechanical hypersensitivity and thigmotaxis following damage to the peripheral nervous system. Functional studies are now required to verify that the products of these genes are indeed involved in the generation and/or maintenance of neuropathic pain. Some of these genes may become targets for developing novel therapeutics to treat neuropathic pain at the level of the primary sensory neurone; where there is probably the most favourable prospect of developing analgesic drugs with a favourable therapeutic index in respect of CNS mediated adverse effects.
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![Paw withdrawal thresholds (PWT) to graded von Frey filaments at day 14 vs. baseline for (A) SNT and (B) gp120 + ddC. Sample size is three rats per replicate for A and two rats per replicate for B. ∗, Significant paired *t* test with *p* \< 0.05 for comparing day 14 with the baseline value. Data are means ± SEM.](gr1){#fig1}

![Heat map of the genes contributing most to the high enrichment score of the pain gene set for (A) gp120 + ddC and (B) SNT. Genes are ranked according to their expression under each experimental condition. For gp120 + ddC there is an association with upregulation, and thus the most differentially expressed genes are shown at the top of the heat map. For SNT there is an association with downregulation and thus the most differentially expressed genes are shown at the bottom of the heat map. Expression values are shown for each replicate within a condition and are represented as colours, where the range of colours (red, pink, light blue, dark blue) shows the range of expression values (high, moderate, low, and lowest).](gr2){#fig2}

![Venn diagrams to cross-compare the lists of significant probe sets (\>1.2-fold difference and 10% FDR) between the SNT and gp120 + ddC models. (A) comparison of upregulated gene lists; (B) comparison of downregulated gene lists.](gr3){#fig3}

![RT-PCR results for TrkB isoforms in gp120 + ddC treated animals. Normalized expression levels for each isoform are expressed as ratios to cyclophilin. Data are expressed as means ± SD. ∗, (*p* \< 0.05) indicates statistical significance between treated and sham groups of animals (Student's *t* test).](gr4){#fig4}

![RT-PCR results for Npy, Pap/Reg2 and Vgf in SNT, gp120 + ddC and VZV infected animals. Normalized expression levels for each gene are expressed as ratios to cyclophilin. Data are expressed as means ± SD. ∗, (*p* \< 0.05) indicates statistical significance between treated and sham groups of animals (Student's *t* test).](gr5){#fig5}

![Immunoblots showing the induction of REG2/PAP protein expression in DRG from sham and SNT-, gp120 + ddC- and VZV-treated animals. The same membrane was re-probed with an anti β-ACTIN antibody.](gr6){#fig6}

###### 

Primer sequences used for RT-PCR

  Gene name   5′ primer               3′ primer                Size (bp)
  ----------- ----------------------- ------------------------ -----------
  TrkB_FL     TCTATGAAGACTGGACCACGC   TTCTCCAAGCTCCCTCTTCAG    449
  TrkB_T1     TCTATGAAGACTGGACCACGC   CCAGTCACAGCTCACAACAAG    422
  TrkB_T2     TCTATGAAGACTGGACCACGC   AGTGGGCAAGGCTGAGTAATC    399
  Npy         ACTGACCCTCGCTCTATCCC    AACGACAACAAGGGAAATGG     400
  Pap/Reg2    TGGCCTTCCCAGTCATGTC     AGATCTTGACAAGCTGCCACAG   445
  Vgf         TACCCAGAACGAGGATTGCG    CAACAGTACCGCGGCCAG       381
  PpiA        ACCCCACCGTGTTCTTCGAC    CATTTGCCATGGACAAGATG     300

###### 

Functional categories of genes highlighted by MAPPFinder for the gp120 + ddC model

  GO name                                       GO type   No. of genes changing/no. of genes measured in the array   *Z* score   Permute *p*
  --------------------------------------------- --------- ---------------------------------------------------------- ----------- -------------
  *Upregulated*                                                                                                                  
  Neuropeptide signalling                       P         4/29                                                       4.852       0
  Hyaluronic acid binding                       F         2/8                                                        4.924       0.003
  Homophilic cell adhesion                      P         4/35                                                       4.281       0.003
  Organ morphogenesis                           P         9/154                                                      3.801       0.004
  Sex differentiation                           P         3/25                                                       3.83        0.005
  Blood vessel morphogenesis                    P         6/83                                                       3.727       0.005
  Regulation of epithelial cell proliferation   P         2/7                                                        5.315       0.006
  Electron carrier activity                     F         5/71                                                       3.326       0.006
  Tube morphogenesis                            P         4/36                                                       4.198       0.008
  Branching morphogenesis of a tube             P         3/22                                                       4.169       0.009
  Axonogenesis                                  P         5/68                                                       3.447       0.009
                                                                                                                                 
  *Downregulated*                                                                                                                
  GABA-A receptor activity                      F         3/8                                                        5.767       0
  Chloride ion binding                          F         3/17                                                       3.577       0.005
  Chloride channel activity                     F         3/18                                                       3.435       0.006

###### 

Gene sets associated with gene upregulation in gp120 + ddC using gene set enrichment analysis

  Name                                    Top 5 genes                               Source                                                         Size   NOM *p*-val   FDR *q*-val
  --------------------------------------- ----------------------------------------- -------------------------------------------------------------- ------ ------------- -------------
  CELL_ADHESION_MOLECULE_ACTIVITY         Ncam1, Mpz, Gp9, L1cam, Cdh1              G0                                                             103    0             0.064
  PELP1PATHWAY                            Mapk3, Pelp1, Crebbp, Ep300, Src          BioCarta                                                       15     0             0.066
  BRENTANI_CELL_ADHESION                  Itga7, Ncam1, Ank1, Jup, Timp2            Brentani et al., Proc Natl Acad Sci USA, 2003, 100:13418--23   123    0             0.068
  ST_GAQ_PATHWAY                          Itpr3, Dag1, Gnaq, Itpr2, Nfkb2           STKE                                                           43     0             0.079
  ST_WNT_CA2_CYCLIC_GMP_PATHWAY           Itpr3, Dag1, Itpr2, Slc6A13               STKE                                                           31     0             0.094
  CELL_ADHESION                           Ptprf, Ncam1, Gpr56, Atp2A2, Jup          G0                                                             178    0             0.148
  PENG_RAPAMYCIN_UP                       Kcnh2, Tp53, Aes, Ucp2, Cd37              Peng et al., Mol. Cell Biol, 2002, 22:5575--84                 153    0             0.157
  PAIN_RELATED                            NpY, TrkB.T1, Cacna1b, Runx1, Penk-rs     NetAffx                                                        257    0             0.159
  CALCIUM_REGULATION_IN_CARDIAC\_ CELLS   Itpr3, Cacna1b, Cacba1c, Atp2a2, Atp1b2   GenMAPP                                                        243    0             0.172
  BRENTANI_SIGNALING                      Stat3, Itga7, Wnt4, Arhgef12, Il6st       Brentani et al., Proc Natl Acad Sci USA, 2003, 100:13418--23   214    0             0.217
  AMINOSUGARS_METABOLISM                  Hk1, Gck, Syb5r3, Hexa, Hk2               KEGG                                                           15     0.002         0.158
  INFLAMMATORY_RESPONSE_PATHWAY           Lamc1, Lama5, Cd40lg, Cd86, Lamc2         Broad Institute                                                29     0.004         0.068
  ST_T\_CELL_SIGNAL_TRANSDUCTION          Dag1, Plcg1, Grb2, Cd3d, Nfkb2            STKE                                                           44     0.005         0.172
  PYK2PATHWAY                             Mapk3, Plcg1, Gnaq, Jun, Grb2             BioCarta                                                       63     0.005         0.206
  INSULIN_SIGNALING                       Npy, Ptprf, Srebf1, Jun, Slc27a4          Broad Institute                                                138    0.006         0.214
  HIFPATHWAY                              Jun, Ep300, Edn1, Hif1a, Creb1            BioCarta                                                       19     0.006         0.074
  STARCH_AND_SUCROSE_METABOLISM           Hk1, Gusb, Gaa, Gck, Gp1                  KEGG                                                           30     0.007         0.164
  G2PATHWAY                               Tp53, Gadd45a, Cdkn2d, Ep300, Cdc25b      BioCarta                                                       28     0.007         0.164
  CALCIUM_HOMEOSTASIS                     Stat3, Casr, Cacna1c, Dnm1, Atp2a2        NetAffx                                                        247    0.007         0.127
  ARAPPATHWAY                             Cltb, Arfgef2, Arfgap1, Pscd1, Pscd2      BioCarta                                                       22     0.009         0.119

Top 5 genes -- top 5 ranking genes belonging to a gene set; source -- source for the gene set; size -- number of genes in a gene set; NOM *p*-val -- nominal *p* value; FDR *q*-val -- false discovery rate.

###### 

Gene sets associated with gene downregulation in gp120 + ddC using gene set enrichment analysis

  Gene set name                            Top 5 genes                             Source                              Size   NOM *p*-val   FDR *q*-val
  ---------------------------------------- --------------------------------------- ----------------------------------- ------ ------------- -------------
  PROTEASOME_DEGRADATION                   Psmc6, Rps27a, Psma4, Psma1, H2afz      Broad Institute                     39     0             2.40e^−04^
  PROTEASOME                               Psma2, Psma4, Psma1, Psma5, Psmb1       GenMAPP                             18     0             3.60e^−04^
  RIBOSOMAL_PROTEINS                       Rps24, Rps27a, Rps25, Rpl21, Rpl7       GenMAPP                             86     0             7.21e^−04^
  STRIATED_MUSCLE_CONTRACTION              Tpm1, Ttn, Tnnt1, Tnni1, Myl2           GenMAPP                             39     0             0.003
  PROTEASOMEPATHWAY                        Psma2, Psma4, Psma1, Psma5, Psmb1       BioCarta                            22     0             0.02
  ELECTRON_TRANSPORT_CHAIN                 Cox6a2, Cox17, Nduf5, Cox7b, Ndyfs4     Broad Institute                     80     0             0.021
  ROME_INSULIN_2F_UP                       Dpysl3, Ppp1r12a, Sh3glb1, Canx, Tpm1   Rome et al., J. Biol. Chem., 2003   204    0             0.161
  DNA_REPLICATION_REACTOME                 Orc3l, Prim2a, Rfc1, Rps27a, Orc4l      GenMAPP                             34     0.002         0.075
  OXIDATIVE_PHOSPHORYLATION                Cox6a2, Ndufa5, Cox7b, Atp6v1d, Atp5o   KEGG                                48     0.003         0.066
  RNA_TRANSCRIPTION_REACTOME               Ccnh, Gtf2f2, Cdk7, Mnat1, Polr2g       GenMAPP                             28     0.009         0.115
  PORPHYRIN_AND_CHLOROPHYLL\_ METABOLISM   Eprs, Blvra, Cp, Urod, Hmox1            GenMAPP                             18     0.020         0.153
  UBIQUITIN_MEDIATED_PROTEOLYSIS           Ube2b, Ube2n, Ube2g1, Ube2d3            GenMAPP                             20     0.022         0.1813

Top 5 genes -- top 5 ranking genes belonging to a gene set; source -- source for the gene set; size -- number of genes in a gene set; NOM *p*-val -- nominal *p* value; FDR *q*-val -- false discovery rate.

###### 

Probe sets upregulated for the SNT and gp120 + ddC models

  Probe set ID    Gene title                                                                  Gene symbol          Fold increase SNT   Fold increase gp120 + ddc
  --------------- --------------------------------------------------------------------------- -------------------- ------------------- ---------------------------
  1373315_at      Aryl hydrocarbon receptor nuclear translocator 2                            Arnt2                1.4                 1.3
  1376911_at      ATPase, Ca^2+^ transporting, plasma membrane 4 (homo sapiens) (predicted)   Atp2B4_predicted     2.9                 1.3
  1376182_at      Bromodomain PHD finger transcription factor (Mus) (predicted)               Bptf_predicted       1.8                 1.2
  1377121_at      Discs, large homolog 5 (Drosophila) (predicted)                             Dlg5\_ predicted     1.5                 1.2
  1383564_at      Interferon regulatory factor 7                                              Irf7                 3.4                 1.2
  1388932_at      Laminin, alpha 5                                                            Lama5                1.8                 1.3
  1377103_at      Midnolin (predicted)                                                        Midn\_ predicted     1.6                 1.3
  1387154_at      Neuropeptide Y                                                              Npy                  8.6                 1.9
  1368238_at      Pancreatitis-associated protein                                             Pap/Reg2             22.3                1.2
  1368303_at      Period homolog 2 (Drosophila)                                               Per2                 2.6                 1.3
  1371910_at      Signal peptide, CUB domain, EGF-like 1 (Mus) (predicted)                    Scube1\_ predicted   1.6                 1.4
  1392238_at      Solute carrier family 4 (anion exchanger), member 8 (Mus) (predicted)       Slc4a8_predicted     2.2                 1.3
  1368359_a\_at   VGF nerve growth factor inducible                                           Vgf                  3.5                 1.3
  1393477_at      --                                                                          --                   5.0                 1.5

--, Unknown.

###### 

Probe sets downregulated for the SNT and gp120 + ddC models

  Probe set ID   Gene title                                                                  Gene symbol            Fold decrease SNT   Fold decrease gp120 + ddc
  -------------- --------------------------------------------------------------------------- ---------------------- ------------------- ---------------------------
  1390892_at     DEP domain containing 1B (predicted)                                        Depdc1b_predicted      2.0                 1.3
  1386120_at     Mus musculus EF hand calcium binding protein 1 (Mus musculus) (predicted)   Efcbp1_predicted       1.7                 1.4
  1381445_at     Estrogen-related receptor gamma                                             Esrrg                  2.5                 1.4
  1376753_at     Fucose-1-phosphate guanylyltransferase                                      Fpgt                   1.7                 1.3
  1382063_at     Galactosidase, alpha                                                        Gla                    1.7                 1.3
  1382787_at     Kinesin family member 5A                                                    Kif5a                  2.0                 1.7
  1396215_at     Similar to RIKEN cDNA 2610022G08                                            LOC502782              1.7                 1.3
  1396117_at     Leucine zipper protein 2 (predicted)                                        Luzp2_predicted        2.0                 1.7
  1397555_at     Leucine zipper protein 2 (predicted)                                        Luzp2\_ predicted      1.4                 2.0
  1393847_at     NFKB inhibitor interacting Ras-like protein 1 (predicted)                   Nkiras1_predicted      1.7                 1.3
  1370122_at     RAB27B, member RAS oncogene family                                          Rab27b                 2.0                 1.7
  1393909_at     Similar to KIAA1841 protein (predicted)                                     RGD1305110_predicted   1.4                 1.7
  1382812_at     Similar to Protein Njmu-R1 (predicted)                                      RGD1310429_predicted   2.0                 1.4
  1378245_at     Similar to 6430514L14Rik protein (predicted)                                RGD1311958_predicted   1.7                 1.3
  1382632_at     Roundabout homolog 2 (Drosophila)                                           Robo2                  2.5                 1.7
  1382477_at     SUMO/sentrin specific protease 5 (predicted)                                Senp5_predicted        1.4                 1.4
  1387435_at     ST8 alpha-*N*-acetyl-neuraminide alpha-2,8-sialyltransferase 3              St8sia3                1.4                 1.3
  1369627_at     Synaptic vesicle glycoprotein 2b                                            Sv2b                   1.7                 2.5
  1394412_at     Transmembrane protein 16C (predicted)                                       Tmem16c\_ predicted    3.3                 1.4
  1392045_at     Transmembrane protein 22                                                    Tmem22                 2.0                 1.3
  1377917_at     Transcribed locus                                                           --                     1.7                 1.4
  1383162_at     --                                                                          --                     1.3                 1.4
  1385972_at     --                                                                          --                     1.4                 1.4
  1392663_at     Transcribed locus                                                           --                     1.7                 1.3
  1396676_at     Transcribed locus                                                           --                     2.7                 1.4

--, Unknown.

[^1]: London Pain Consortium.
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